Related Experiment Video
Updated: Jul 18, 2026

Cultivating Ex Vivo Patient-Derived Glioma Organoids Using a Tissue Chopper
Published on: January 19, 2024
Glioblastoma--the consequences of advanced patient age on treatment and survival
Andreas M Stark1, Jürgen Hedderich, Janka Held-Feindt
1Department of Neurosurgery, University of Schleswig-Holstein Medical Center Campus Kiel, Schittenhelmstr. 10, 24105 Kiel, Germany. starka@nch.uni-kiel.de
Abstract:
Glioblastoma is the most common primary brain tumor. Recent evidence suggests that aggressive treatment is also effective in elderly patients. However, large patient series are missing. The aim of this retrospective study was to determine prognostic factors in a large series (n=345) of elderly patients surgically treated for newly diagnosed glioblastoma (WHO grade IV) at a single institution between 1991 and 2002. U-tests (Mann Whitney), chi-square tests, log-rank tests/Kaplan-Meier plots and Cox regression models were used for statistical analysis. Based on the maximum difference in median survival, a threshold of 60 years was used to separate younger from older patients. In total, 185 patients (53.6%) were over 60 years old. In these individuals, total tumor resection, radiotherapy and reoperation for tumor recurrence were identified as independent prognostic factors. When total surgical resection was combined with radiotherapy and reoperation, Kaplan-Meier analysis revealed a median survival of up to 64 weeks in elderly patients. Our data indicate that total tumor resection, radiotherapy and reoperation should also be considered in selected elderly patients. Age alone should not generally exclude elderly individuals from aggressive treatment.
Related Concept Videos
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Pharmacodynamics in Geriatric Patients: Effects of Age
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug Dosing: Geriatric Patients
Treatment Resistant Cancers
